Provided by Tiger Trade Technology Pte. Ltd.

Castle Biosciences, Inc.

35.56
+0.30500.87%
Post-market: 35.560.00000.00%19:30 EDT
Volume:167.72K
Turnover:5.94M
Market Cap:1.09B
PE:-54.36
High:35.92
Open:35.56
Low:34.75
Close:35.26
52wk High:44.28
52wk Low:17.72
Shares:30.55M
Float Shares:28.22M
Volume Ratio:0.39
T/O Rate:0.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6542
EPS(LYR):-0.8334
ROE:-4.20%
ROA:-1.36%
PB:2.31
PE(LYR):-42.67

Loading ...

Castle Biosciences Chief Commercial Officer W. Juvenal Tobin Disposes of $232,140 in Common Shares

Reuters
·
Oct 02

Castle Biosciences Says Prospective Study Shows Low-Risk DecisionDx-Melanoma Results Link to 4.4% SLN Positivity, 99.6% Five-Year RFS Without SLNB

Reuters
·
Oct 01

Castle Biosciences: Study shows TissueCypher test changed management

TIPRANKS
·
Sep 28

Castle Biosciences Says TissueCypher Test Drives Management Changes in 90% of Non-Dysplastic Barrett’s Patients in New Study

Reuters
·
Sep 28

Castle Biosciences Study Finds 83% of Atopic Dermatitis Patients Interested in Molecular Testing to Guide Systemic Therapy Choice

Reuters
·
Sep 25

Castle Biosciences CEO Derek J. Maetzold Trims Stake by 14,496 Shares Worth $512,445.26

Reuters
·
Sep 24

Castle Biosciences to Open New Lab in Arizona

MT Newswires Live
·
Sep 22

Castle Biosciences, - Opens New Laboratory and Office Facility in Scottsdale, Arizona

THOMSON REUTERS
·
Sep 22

Castle Biosciences Chief Commercial Officer Juvenal Tobin Disposes of USD 221,875.04 in Common Shares

Reuters
·
Sep 17

Castle Biosciences’ TissueCypher shows improvement in Barrett’s esophagus

TIPRANKS
·
Sep 15

Castle Biosciences publishes DecisionDx-SCC test result study in JAAD

TIPRANKS
·
Sep 10

Castle Biosciences Says JAAD Study Validates Integrated DecisionDx-SCC Test in High-Risk Skin Cancer Cohort of 572 Patients

Reuters
·
Sep 10

SciBase Gets Additional Order from Castle Biosciences

Reuters
·
Sep 08

SciBase Receives Additional Castle Biosciences Order, Expands Collaboration

Reuters
·
Sep 08

Castle Biosciences COO Kristen Oelschlager Reports Disposal of Common Shares Worth $138,510.72

Reuters
·
Sep 04

Castle Biosciences CEO Derek Maetzold Disposes of USD 581,331 in Common Shares

Reuters
·
Sep 02

Castle Biosciences Chief Commercial Officer Juvenal Tobin Sells 9,050 Shares for $317,112.00

Reuters
·
Aug 28

Castle Biosciences to Present at Baird Global Healthcare Conference

Reuters
·
Aug 20

Castle Biosciences CEO Derek Maetzold Sells USD 203,642 of Common Shares

Reuters
·
Aug 19

Castle Biosciences Gets Approval for Dual Listing on Nasdaq Texas

MT Newswires Live
·
Aug 17